RECURSION PHARMACEUTICALS-A (RXRX)
US75629V1044 - Common Stock
We assign a fundamental rating of 3 out of 10 to RXRX. RXRX was compared to 582 industry peers in the Biotechnology industry. The financial health of RXRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, RXRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RXRX had negative earnings in the past year.
In the past year RXRX has reported a negative cash flow from operations.
RXRX had negative earnings in each of the past 5 years.
RXRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -63.48%, RXRX is doing worse than 62.05% of the companies in the same industry.
With a Return On Equity value of -88.28%, RXRX perfoms like the industry average, outperforming 47.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.48% | ||
| ROE | -88.28% | ||
| ROIC | N/A |
ROA(3y)-38.3%
ROA(5y)-41.01%
ROE(3y)-51.48%
ROE(5y)-54.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RXRX's Gross Margin of 10.68% is fine compared to the rest of the industry. RXRX outperforms 74.35% of its industry peers.
RXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RXRX has been increased compared to 1 year ago.
Compared to 1 year ago, RXRX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.38 indicates that RXRX is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.38, RXRX is doing good in the industry, outperforming 77.30% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that RXRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, RXRX is in line with its industry, outperforming 48.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.38 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
A Current Ratio of 4.65 indicates that RXRX has no problem at all paying its short term obligations.
RXRX has a Current ratio (4.65) which is in line with its industry peers.
RXRX has a Quick Ratio of 4.65. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
RXRX has a Quick ratio (4.65) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.65 |
3. Growth
3.1 Past
RXRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.39%.
RXRX shows a decrease in Revenue. In the last year, the revenue decreased by -0.87%.
RXRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 124.11% yearly.
EPS 1Y (TTM)-17.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.71%
Revenue 1Y (TTM)-0.87%
Revenue growth 3Y124.11%
Revenue growth 5YN/A
Sales Q2Q%13.68%
3.2 Future
RXRX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.02% yearly.
The Revenue is expected to grow by 42.61% on average over the next years. This is a very strong growth
EPS Next Y-8.78%
EPS Next 2Y-10.18%
EPS Next 3Y-0.02%
EPS Next 5YN/A
Revenue Next Year12.99%
Revenue Next 2Y31.71%
Revenue Next 3Y42.61%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RXRX. In the last year negative earnings were reported.
Also next year RXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.18%
EPS Next 3Y-0.02%
5. Dividend
5.1 Amount
RXRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RECURSION PHARMACEUTICALS-A
NASDAQ:RXRX (6/14/2024, 7:00:01 PM)
After market: 9.17 -0.09 (-0.97%)9.26
-0.18 (-1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.20B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.48% | ||
| ROE | -88.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.68% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-17.39%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-8.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.87%
Revenue growth 3Y124.11%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y